Uncategorized

Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab

Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab

Published

on

Pathos AI could pay more than $2 billion to a Jiangsu Alphamab Biopharmaceuticals subsidiary for a late-stage bispecific antibody-drug conjugate for breast cancer, while the financial details of the AstraZeneca agreement were not disclosed.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version